What is Roth Capital’s Estimate for BRTX FY2028 Earnings?

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Research analysts at Roth Capital reduced their FY2028 earnings per share (EPS) estimates for BioRestorative Therapies in a report released on Thursday, November 14th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of $5.40 for the year, down from their prior estimate of $5.43. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.76) per share.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.30 million.

Separately, Roth Mkm increased their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Price Performance

Shares of BRTX opened at $1.47 on Friday. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $3.67. The company has a market capitalization of $10.17 million, a P/E ratio of -0.95 and a beta of 63.40. The firm’s 50 day simple moving average is $1.63 and its 200 day simple moving average is $1.59.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.